SpectraCure AB (SPEC) fair value: what the stock is really worth
As of Sep 24, 2026: fair value of SpectraCure AB SEK 0.01, price SEK 0.02, upside -21.2%, quality 16 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch SpectraCure AB for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
SpectraCure AB (publ) engages in the development of cancer treatment system in Sweden. It develops Q-PRO, a laser unit; IDOSE software platform, which calculates the optimal laser light dose and placement of the optical fibers; and disposable items comprising needles, optical fibers, and light-sensitive medication.
Show more
SpectraCure AB (publ) engages in the development of cancer treatment system in Sweden. It develops Q-PRO, a laser unit; IDOSE software platform, which calculates the optimal laser light dose and placement of the optical fibers; and disposable items comprising needles, optical fibers, and light-sensitive medication. The company was incorporated in 2003 and is based in Lund, Sweden.
Stock analysis
SpectraCure AB (SPEC) currently trades at kr 0.0184, while our model-based Fair Value estimate is kr 0.0145, implying the stock looks roughly 26.9% overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the evidence level at low.
Quality & growth
The Quality Score stands at 16/100 (below-average quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
SpectraCure AB reported revenue of 868K SEK in FY2025 versus 5.7M SEK in FY2021, a compound −37.7%/yr. Reported net income was −56.1M SEK in FY2025.
Key figures
Market cap 28.5M SEK (≈ $2.9M) · P/S ratio 43.9 · EPS (TTM) kr −0.0500 · Return on equity −40.2% · Return on assets (EBIT) −23.3% · Operating margin −2,338% · Revenue (TTM) 649K SEK · Revenue growth (YoY) −43.3%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 35 out of 100 (low confidence).
What moves the price
The share trades about 92% below its 52-week high and 1% above its 52-week low.
For context, the median of 10 Healthcare peers we cover trades at 5% fair-value upside, at −21%, SPEC screens richer than that median.
Fair Value models
Bear kr 0.0145Fair Value kr 0.0145Bull kr 0.0145
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.32/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
−95.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+17.2%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+272.5%
Start year 2020 (pandemic). Over 10 years: +1.1% a year
Revenue growth 12 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−4.4%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−1,359,620.1% (2020) → −6,261.9% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 365 stocks
Beats the industry median on 0/5 measures
Overall it trails its industry peers.
Valuation
Quality Score20 · Bottom 25%
Fair Value upside−20% · Below median
Profitability
Return on assets−28% · Bottom 25%
Growth and dividend
Revenue growth−43% · Bottom 25%
Valuation Multiplesvs Medical Devices median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "SpectraCure AB Fair Value". https://www.fairvalue-calculator.com/stock/SPEC
Frequently asked questions
Is SpectraCure AB (SPEC) overvalued or undervalued?
As of Sep 23, 2026, our model estimates a fair value of kr 0.0145 versus a price of kr 0.0184, about −21% upside (overvalued).
What is the fair value of SPEC?
Our model-based fair value for SpectraCure AB is kr 0.0145 (as of Sep 23, 2026), built from audited fundamentals. The current price: kr 0.0184.
What is the quality score of SPEC?
SpectraCure AB has a Quality Score of 16/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for SpectraCure AB (SPEC)?
Our model-based price target is the fair value of kr 0.0145 (as of Sep 23, 2026) from 1 valuation models. It is a calculation from audited fundamentals, not an analyst target.
What is the SpectraCure AB stock forecast for 2026?
Our models put fair value at kr 0.0145, about −21% upside versus a price of kr 0.0184 (overvalued). The calculation is refreshed regularly with new filings.
What is the revenue of SpectraCure AB (SPEC)?
SpectraCure AB reported trailing-twelve-month revenue of about 649K SEK (latest available figure, as of Sep 23, 2026).
What is the intrinsic value of SpectraCure AB (SPEC)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For SpectraCure AB it is kr 0.0145 per share (as of Sep 23, 2026), against a price of kr 0.0184. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is SpectraCure AB stock overvalued or undervalued in 2026?
As of Sep 23, 2026, SPEC trades above its calculated fair value: price kr 0.0184, fair value kr 0.0145, a gap of about −21% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of SPEC?
No. The price is what the market pays today (kr 0.0184); the fair value is what the company's own numbers justify (kr 0.0145). For SpectraCure AB the two are kr 0.0039 per share apart. That gap is exactly why we show both numbers side by side.
How much is SpectraCure AB worth?
The market values SpectraCure AB at about 28.5M SEK (market capitalisation, as of Sep 23, 2026). Per share that is kr 0.0184; our models calculate a fair value of kr 0.0145 per share.
How solid is the balance sheet of SpectraCure AB (SPEC)?
Balance-sheet figures for SpectraCure AB (as of Sep 23, 2026): return on equity −40.2%. They feed the Quality Score of 16/100, which measures business quality independently of the share price.
How far is SPEC from its 52-week high?
SpectraCure AB trades at kr 0.0184, about 92% below its 52-week high of kr 0.2300 and 1% above the low of kr 0.0182 (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of kr 0.0145 is for.
Which stocks are comparable to SpectraCure AB?
From the same area (Healthcare) we also value Abbott Laboratories,, Stryker Corporation, Medtronic plc, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is SpectraCure AB stock attractive at the current price?
The data as of Sep 23, 2026: price kr 0.0184, calculated fair value kr 0.0145 (−21%), Quality Score 16/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of SPEC calculated?
We run SpectraCure AB through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of kr 0.0145, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0 % above its aggregate fair value. SpectraCure AB itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of SpectraCure AB (SPEC)?
The closing price on Sep 24, 2026 was kr 0.0184. Our model-based fair value is kr 0.0145, about −21% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with SpectraCure AB right now?
The price sits above even our optimistic bull case (kr 0.0145). The favourable scenario is already priced in. Weak quality (16/100) and above fair value at the same time, the margin of safety is missing on both counts. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Key figures of SpectraCure AB
How large is the market capitalisation of SpectraCure AB (SPEC)?
The market capitalisation of SpectraCure AB is 28.5M SEK (≈ $2.9M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of SpectraCure AB (SPEC)?
The price-to-sales ratio of SpectraCure AB is 43.9 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of SpectraCure AB (SPEC)?
Earnings per share at SpectraCure AB are kr −0.0500. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of SpectraCure AB (SPEC)?
The return on equity (ROE) of SpectraCure AB is −40.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of SpectraCure AB (SPEC)?
On an EBIT basis the return on assets of SpectraCure AB is −23.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of SpectraCure AB (SPEC)?
The operating margin of SpectraCure AB is −2,338% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at SpectraCure AB (SPEC)?
Revenue at SpectraCure AB is growing −43.3% versus a year earlier (3y avg +17.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does SpectraCure AB (SPEC) generate?
The free cash flow of SpectraCure AB is −24.0M SEK (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does SpectraCure AB (SPEC) hold?
SpectraCure AB holds more cash than debt, 10.5M SEK net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch SpectraCure AB in the live analysis
One click puts SpectraCure AB on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
